tbuckley/cabot-search huggingface dataset:
An assessment of the need for follow-up of patients with pulmonary tuberculosis adequately treated by chemotherapy.
Journal: BMJ (1975)

Until recently the treatment of tuberculosis was so unsatisfactory that patients who survived were kept under indefinite supervision because relapse was frequent.As well as clinical, radiological, and bacteriological examination this entailed advice over much of the patient's life-work, recreation, child-bearing, and so on.Now such is the efficacy of antituberculous treatment that the time is ripe for a revaluation of the need for supervision.Evidence will be presented to show that with certain important exceptions, and, with safeguards, patients believed to have taken prescribed adequate chemotherapy (see below) need not be kept under supervision.The exceptions will be mentioned first.They are patients with "high risk factors." High Risk FactorsPoor co-operation leading to inadequate treatment is the most important factor in relapse.Every effort must therefore be made to identify uncooperative patients early.There is a hard core of persons with psychopathic traits who will never co-operate (unless in a prison hospital), and some with other psychiatric disorders fail to do so, but there are others who need constant encouragement to retain their co-operation.A good doctor-patient relationship is most important, and the health visitor too has a valuable role.Spot tests on urine are most important.The patient must be made to understand that he will become well and remain well only if he takes the prescribed treatment.Unfortunately patients who fail to take the treatment are apt not to attend for follow-up.Co-operation may be easier to achieve now that PAS is being replaced by more acceptable drugs, for its side effects may frequently have deterred patients from continuing with treatment.
Medicine Man
Authors: Joe Sample
Journal: JAMA (1990)

This book is a treat for several groups of readers. Regionalists will enjoy this remembrance of turn-of-the-century life in the Pacific Northwest. Historians of the American West will have yet another personal account to flesh out their academic histories. Physicians will take special delight in this volume, as they read of one man's progression from novice medical graduate to accomplished country doctor. The author, Owen Tully Stratton, recorded his observations and reflections in journals written over 30 years, encompassing his life as a medicine show pitchman in the Pacific Northwest from 1898 to 1904 and as a country doctor in the same area from 1906 to 1950. Though he may have tried for publication at an earlier date, his writings were put away and considered by his family to be lost until they resurfaced 35 years after the author's death. His younger son, Owen S. Stratton, professor emeritus of political
Family Practice
Authors: Robert E. Rakel
Journal: JAMA (1989)

Events of the past 10 years have left many physicians reeling from professional shock and wondering how the practice of medicine as they once knew it could have changed so dramatically. Increasing competition, the advent of prospective payment and managed care, the evolving role of peer review, the malpractice crisis, and other changes have introduced new challenges to medicine, challenges that have tested many physicians' enthusiasm for their chosen profession. Even so, a more far-reaching change looms on the horizon, a change that will reflect a growing public-policy mandate and bring to full circle the philosophical course charted a quarter-century ago through Medicare. Despite having what some people consider the best health care system in the world, many Americans find themselves on the outside looking in. Over 40 million people are disenfranchised from health care to one extent or another by not having adequate health insurance. Many of these people
Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy
Authors: A. A. Skolnick
Journal: JAMA (1997)

A COMPOUND first isolated from a traditional Chinese herbal medicine may lead to new therapeutic agents for Alzheimer disease (AD). Based on laboratory and x-ray crystallography studies, these agents, some researchers think, could be even better than the 2 drugs already approved for the disease. The alkaloid compound, huperzine A (HupA), was discovered in the Chinese herbal medicine<i>Qian Ceng Ta</i>. This traditional remedy, which is prepared from the moss<i>Huperzia serrata</i>, has been used in China for centuries to treat fever and inflammation. Although it has no antipyretic or antiinflammatory properties, HupA does appear to be a potent inhibitor of acetylcholinesterase (AChE). In addition to appearing more selective and possibly less toxic than the 2 AChE inhibitors currently approved for the treatment of AD, HupA has a number of other pharmacological properties of clinical interest, said Israel Silman, PhD, professor of neurobiology at the Weizmann Institute of Science, Rehovot,
Journal de Médecine de Lyon
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Khirurgiia, Moscow
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Environmental tobacco smoke and heart disease: a correction
Authors: D. Rennie
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypoplastic Enamel Associated with Nephrotic Syndrome
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
History of the Royal Hungarian Francis Joseph University of Sciences, Founded at Kolozsvár in 1872, and Re-Opened at Szeged in 1921.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA (2014)

Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is hypothesized to play a causal role in the development of atherosclerosis and to contribute to atherosclerotic plaque instability.In a randomized, placebo-controlled trial that enrolled 13 026 patients who had experienced an acute coronary syndrome in the past 30 days, O'Donoghue and colleagues found that darapladib-an inhibitor of Lp-PLA 2 -added to optimal medical therapy did reduce the risk of major coronary events during 2.5 years of follow-up. Perioperative Colchicine and Postpericardiotomy Syndrome 1016Postpericardiotomy syndrome and postoperative atrial fibrillation and effusions are common complications of cardiac surgery.Preliminary data suggest that postoperative administration of colchicine may prevent these complications.To assess whether this potential benefit might be enhanced with earlier initiation of colchicine, Imazio and colleagues randomly assigned 360 patients scheduled for cardiac surgery to receive colchicine or placebo beginning between 48 and 72 hours before surgery and continued for 1 month after surgery.The authors report that compared with placebo, perioperative use of colchicine reduced the incidence of postpericardiotomy syndrome but not postoperative atrial fibrillation or effusions.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Authors: Josef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B McInnes, Alexandre Sepriano, Ronald F van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, John Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Mario Humberto Cardiel, Diederik De Cock, Catalin Codreanu, Maurizio Cutolo, Christopher John Edwards, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques-Eric Gottenberg, Merete Lund Hetland, Tom W J Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller-Ladner, Eduardo F Mysler, Jose A P da Silva, Gyula Poór, Janet E Pope, Andrea Rubbert-Roth, Adeline Ruyssen-Witrand, Kenneth G Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
Journal: Annals of the Rheumatic Diseases (2020)

To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field.An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items.The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high.These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.
Digital Thermometer
Authors: Robert S. Golden
Journal: Annals of Internal Medicine (2011)

Ad Libitum4 October 2011Digital ThermometerRobert S. Golden, MDRobert S. Golden, MDFrom Northwestern University Feinberg School of Medicine, Chicago, IL 60611.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-7-201110040-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A Filac f-1500 digital thermometerquietly sits in our lab and bides its time.It knows it will be called into serviceeventually, just as soon as I'mseeing a patient with the flu or a rash.It looks pretty old, white plastic now yellow.It waits silently for its turn with a patient,like the lady in room 6, or maybe the fellowin room 3 with the cough that makes it quite hardto keep his mouth shut long enough to acquirethe data that's needed to report accurately.Is his temp 98.6, or perhaps is it higher?They move from ... Author, Article, and Disclosure InformationAffiliations: From Northwestern University Feinberg School of Medicine, Chicago, IL 60611.Current Author Address: Robert S. Golden, MD, Northwestern University Feinberg School of Medicine, 201 East Huron, #12-205, Chicago, IL 60611. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 October 2011Volume 155, Issue 7Page: 476KeywordsInterleukinsMouthRashesThermometers ePublished: 4 October 2011 Issue Published: 4 October 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Management of gastric intestinal metaplasia in the UK: a preliminary survey
Authors: R. Pandey, A. Millar
Journal: Gut (2011)

The rarity of congenital hypopituitarism (CHP) makes it essential for clinicians to be aware of its varying clinical manifestations. We report a neonate with one such unique presentation. A preterm girl baby was managed for respiratory distress. Diffuse cutis marmorata was present since birth; septic screens were positive with placental histopathology showing chorioamnionitis. Newborn screening showed low free thyroxine and normal TSH. Transient hypothyroxinaemia of prematurity was considered. Her respiratory status worsened on day 9, followed by refractory shock. She was treated for sepsis. Further evaluation for absent heart rate variability in response to vasopressor resistant shock led to the detection of hypocortisolism. Low cortisol along with hypothyroxinaemia made hypopituitarism the working diagnosis. Owing to the variable clinical spectrum of CHP, diagnosis is challenging. We highlight a few clinical and laboratory features, which would help in earlier diagnosis of CHP.
INFORMATION ABOUT THE SUPERITENDENT OF DOCUMENTS SUBSCRIPTION SERVICE
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article INFORMATION ABOUT THE SUPERITENDENT OF DOCUMENTS SUBSCRIPTION SERVICE Get access JNCI: Journal of the National Cancer Institute, Volume 81, Issue 1, January 1989, Page 79, https://doi.org/10.1093/jnci/81.1.79 Published: 01 January 1989
Journal of Infectious Diseases, Chicago
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
State-Specific Pregnancy and Birth Rates Among Teenagers—United States, 1991-1992
Journal: JAMA (1995)

Pregnancy and childbearing rates for teenagers remain high in the United States despite well-documented associated adverse health, social, and economic consequences for many of these teenagers and their children. In 1990, approximately 835,000 (10%) teenagers aged 15-19 years became pregnant and either gave birth or had an abortion (CDC, unpublished data, 1995); an estimated 95% of such pregnancies are unintended (1). This report presents estimates of pregnancy rates among women aged < or = 19 years for each state and the District of Columbia (DC) by age group, pregnancy rates for women aged 15-19 years by race, and birth rates for women aged 15-19 years by race and by Hispanic ethnicity for 1991-1992, and compares pregnancy rates for 1991 and 1992.
Medical devices sorted into classes, regulated
Authors: M. F. Goldsmith
Journal: JAMA (1985)

For the past nine years, the Office of Device Evaluation of the FDA's Center for Devices and Radiological Health has been working on the mammoth task of sorting all the medical devices that were on the market as of 1976 into three classes and regulating their use. According to Robert L. Sheridan, the office's associate director, about half the job is completed. The office has designated 16 medical disciplines and written final regulations for thousands of devices, from the simplest to the most complex, used in nine of those disciplines. Regulations have been proposed for the remaining seven. At the same time, the office's 190 employees—about 110 scientists and 80 administrative and secretarial staff—continue to process about 9,000 documents per year dealing with new devices. They review proposed clinical investigations and decide whether a new device can legally go to market. "We produce paper here," Sheridan says. "We're a manufacturing